___

• 1. Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002;121:877–905. 2. Konstantinides S. Pulmonary embolism: impact of right ventricular dysfunction. Curr Opin Cardiol 2005;20: 496–501. 3. Alikhan R, Peters F, Wilmott R, and Cohen AT. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol 2004;57: 1254–57. 4. Heit JA, O’Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:1245–48. 5. de Boer RA, Yu L, and van Veldhuisen DJ. Galactin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010;7: 1-8. 6. Kimura Y, Izumiya Y, Hanatani S, Yamamoto E, Kusaka H, Tokitsu T, et al. High serum levels of thrombospondin-2 correlate with poor prognosis of patients with heart failure with preserved ejection fraction. Heart Vessels 2014; DOI: 10.1007/s00380-014-0571-y. 7. Pacienza N, Pozner RG, Bianco GA, D'Atri LP, Croci DO, Negrotto S, et al. The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation. FASEB J 2008;22:1113-23. 8. Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D'Angelo A, Schirinzi S, al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol 2011;24:905 9. Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, et al. Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22. Clin Chem 2012;58: 267-73. 10. Ramacciotti E, Hawley AE, Wrobleski SK, Myers DD Jr, Strahler JR, Andrews PC, et al. Proteomics of microparticles after deep venous thrombosis. Thromb Res 2010;125:269-74.